Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana

Mosepele, Mosepele; Letsatsi, Virginia; Mokgatlhe, Lucky; Hudson, Frank P.; Gross, Robert

doi:10.2174/1874613601711010045

Cited by 9 publications

(9 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, smoking prevalence in the setting of their pilot study was estimated to be as high as 51% for male candidates and 6% for female candidates with HIV infection. 39 There were proportionately fewer female candidates enrolled in the present study consistent with data from demographic and health surveys in sub-Saharan Africa. 40 Although these smoking rates appear to be comparatively lower than reports from North America and Europe, these rates are projected to increase in the African continent whilst they are falling in other parts of the world.…”

Section: Discussionsupporting

confidence: 82%

Feasibility of implementing a novel behavioural smoking cessation intervention amongst human immunodeficiency virus-infected smokers in a resource-limited setting: A single-arm pilot trial

Tsima

Motlokwa

Maunge³

et al. 2020

Southern African Journal of HIV Medicine

View full text Add to dashboard Cite

Background: Tobacco use is prevalent amongst individuals infected with human immunodeficiency virus (HIV). In resource-constrained settings, pharmacological smoking cessation interventions are unfeasible because of their high cost. There is a need to develop and evaluate behavioural interventions to address the unique challenges of tobacco use in the HIV-infected populations in these settings.Objectives: The authors aimed to assess the feasibility and acceptability of the Behavioural Activation/Problem Solving for Smoking Cessation (BAPS-SC) intervention programme to determine whether it should be tested in an adequately powered randomised controlled trial.Method: The authors merged behavioural activation therapy (BAT) with the principles of problem-solving therapy to create a novel five-session counselling model to address the unique challenges of tobacco cessation amongst those infected with HIV. Feasibility measures included the rate of enrolment amongst those eligible and the retention rate and descriptive analysis of intervention acceptability. The authors’ secondary outcome was 7-day point smoking prevalence abstinence, confirmed with breath carbon monoxide.Results: A total of 128 individuals were screened over 8 weeks with 50 deemed eligible and 40 enrolled (80%). Retention at week 12 was 53% (21/40). The 7-day point prevalence abstinence, co-confirmed, at week 12 was 37.5% (15/40). All respondents indicated that they would recommend BAPS-SC to other smokers who want to quit, and would be willing to participate in the programme again up to the point of exit if they did not stop smoking.Conclusion: A full-scale randomised control trial comparing BAPS-SC with usual practice is warranted to evaluate the efficacy of this novel intervention in these settings.

show abstract

Section: Discussionsupporting

confidence: 82%

Feasibility of implementing a novel behavioural smoking cessation intervention amongst human immunodeficiency virus-infected smokers in a resource-limited setting: A single-arm pilot trial

Tsima

Motlokwa

Maunge³

et al. 2020

Southern African Journal of HIV Medicine

View full text Add to dashboard Cite

show abstract

“…For instance, in a nationally representative survey representing 2.2 million HIV-infected adults’ clinic visits versus 602 million clinic visits for HIV-uninfected adults, statin prescription rates were significantly lower (23.6% versus 35.8%, p<0.01) among HIV-infected versus HIV-uninfected [68]. In Botswana, a resource limited setting, only 1% of the estimated 14% HIV-infected adults recommended statin therapy by the 2013 ACC/AHA guidelines were actually prescribed statin therapy [63]. With regard to actual physician-reported behavior towards statin prescription, 43% of Italian physicians reported prescribing statins to HIV-infected patients who were recommended statin therapy as per the European AIDS Clinical Society recommendations [69].…”

Section: Statin Prescription In Routine Hiv Carementioning

confidence: 99%

Benefits and Risks of Statin Therapy in the HIV-Infected Population

Mosepele

Molefe-Baikai

Grinspoon

et al. 2018

Curr Infect Dis Rep

View full text Add to dashboard Cite

Statins remain the preferred agents for reducing risk for CVD among HIV-infected populations based on guidance extrapolated from general population (HIV-uninfected) cholesterol treatment guidelines across different settings globally. However, HIV-infected patients are consistently under prescribed statin therapy when compared to their HIV-uninfected counterparts. The most commonly studied statins in clinical care and small randomized and cohort studies have been rosuvastatin and atorvastatin. Both agents are preferred for their potent lipid-lowering effects and their favorable or neutral pleotropic effects on chronic inflammation, renal function, and hepatic steatosis among others. However, growing experience with the newer glucuronidated pitavastatin suggests that this agent has virtually no adverse drug interactions with ART or effects on glucose metabolism-all marked additional benefits when compared with rosuvastatin and atorvastatin while maintaining comparable anti-lipid effects. Pitavastatin is therefore the statin of choice for the ongoing largest trial (6500 participants) to test the benefits of statin therapy among HIV-infected adults. Statins are underutilized in the prevention of CVD in HIV-infected populations based on criteria in established cholesterol guidelines. There is a potential role for statin therapy for HIV-infected patients who do not meet guideline criteria which will be further delineated through ongoing clinical trials.

show abstract

“…Лечение ингибиторами протеаз способствует развитию дислипидемии, формированию каротидных бляшек в 37% случаев [56]. Неназначение статинов лицам, принимающим ингибиторы протеазы, увеличивает риск сердечно-сосудистых осложнений [57]. Плазменные уровни ХС ЛПНП и ХСЛПВП коррелируют с увеличением толщины комплекса интимамедиа каротидных артерий в динамике на фоне начала приема АРТ наивными ВИЧ-инфицированными пациентами [58].…”

Section: влияние антиретровирусной терапии на миокард и сосуды у вич-unclassified

HIV-associated cardiovascular pathology

2019

View full text Add to dashboard Cite

АРТ-антиретровирусная терапия, ВИЧ-вирус иммунодефицита человека, ОХС-общий холестерин, СН-сердечная недостаточность, ХС ЛПВП-холестерин липопротеидов высокой плотности, ХС ЛПНП-холестерин липопротеидов низкой плотности, ХС ЛПОНП-холестерин липопротеидов очень низкой плотности, ХОБЛ-хроническая обструктивная болезнь легких, ЭКГ-электрокардиография, TFPI-ингибитор пути тканевого фактора, CCL24-лиганд 24 хемокина СС-модифицированного, NT-proBNP-N-терминальный фрагмент мозгового натрийуретического пептида, MBL2-лектин-2, связывающий маннозу, LTBR-бета-рецептор лимфотоксина, PCOLCE-интенсификатор эндопептидазы-С проколлагена.

show abstract

Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana

Abstract: Abstract:Background:

Cited by 9 publications

References 21 publications

Feasibility of implementing a novel behavioural smoking cessation intervention amongst human immunodeficiency virus-infected smokers in a resource-limited setting: A single-arm pilot trial

Feasibility of implementing a novel behavioural smoking cessation intervention amongst human immunodeficiency virus-infected smokers in a resource-limited setting: A single-arm pilot trial

Benefits and Risks of Statin Therapy in the HIV-Infected Population

HIV-associated cardiovascular pathology

Contact Info

Product

Resources

About